Thomas Blaettler

Thomas Blaettler currently serves as the Chief Medical Officer and Head of Global Clinical Development at Vectura Fertin Pharma since May 2023. Previously, Thomas held the Chief Medical Officer position at Coave Therapeutics from November 2021 to April 2023 and at Orphazyme A/S from November 2016 to October 2021. Thomas's extensive experience at Roche from 2009 to 2016 included roles such as PD Group Medical Director in Neuroscience and leading the Olesoxime Global Development program. Earlier positions include Medical Director at Bristol-Myers Squibb and Translational Medicine Expert II at Novartis. Thomas earned an MD from the University of Zurich from 1988 to 1994.